MXPA02011545A - Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela. - Google Patents

Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.

Info

Publication number
MXPA02011545A
MXPA02011545A MXPA02011545A MXPA02011545A MXPA02011545A MX PA02011545 A MXPA02011545 A MX PA02011545A MX PA02011545 A MXPA02011545 A MX PA02011545A MX PA02011545 A MXPA02011545 A MX PA02011545A MX PA02011545 A MXPA02011545 A MX PA02011545A
Authority
MX
Mexico
Prior art keywords
respiratory syndrome
porcine reproductive
syndrome virus
prrsv
vaccine
Prior art date
Application number
MXPA02011545A
Other languages
English (en)
Inventor
Jennifer Maria Perez
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Sas filed Critical Merial Sas
Publication of MXPA02011545A publication Critical patent/MXPA02011545A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24041Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/10011Arteriviridae
    • C12N2770/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/10011Arteriviridae
    • C12N2770/10034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Lo que se describe es un vector recombinante, tal como un virus, por ejemplo, un virus de la viruela, tal como el virus de la viruela de las aves, que contiene un ADN externo del virus del sindrome respiratorio y reproductor porcino. Lo que también se describe son composiciones inmunologicas que contienen el virus de viruela recombinante, para inducir una respuesta inmunologica en un animal hospedador, al cual se le administra la composicion inmunologica. También se describen métodos para el tratamiento o prevencion de enfermedades causadas por el virus del sindrome respiratorio y reproductor porcino, al administrar las composiciones inmunologicas de la invencion a un animal que necesite del tratamiento o que sea susceptible a la infeccion por el virus del sindrome respiratorio y reproductor porcino.
MXPA02011545A 2000-05-24 2001-05-18 Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela. MXPA02011545A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20665500P 2000-05-24 2000-05-24
PCT/IB2001/000870 WO2001089559A2 (en) 2000-05-24 2001-05-18 Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine

Publications (1)

Publication Number Publication Date
MXPA02011545A true MXPA02011545A (es) 2003-06-06

Family

ID=22767352

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011545A MXPA02011545A (es) 2000-05-24 2001-05-18 Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.

Country Status (12)

Country Link
US (1) US20030003112A1 (es)
EP (1) EP1283718A2 (es)
JP (1) JP2003533989A (es)
KR (1) KR20030036194A (es)
CN (1) CN1443076A (es)
AU (1) AU2001256582A1 (es)
BR (1) BR0111366A (es)
CA (1) CA2409874A1 (es)
MX (1) MXPA02011545A (es)
PL (1) PL360096A1 (es)
WO (1) WO2001089559A2 (es)
ZA (1) ZA200210230B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
ES2256323T5 (es) 2000-11-23 2016-11-21 Bavarian Nordic A/S Variante del virus Vaccinia Ankara Modificado
US7628980B2 (en) 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
KR20030082960A (ko) * 2001-03-09 2003-10-23 베링거잉겔하임베트메디카게엠베하 Prrs 바이러스의 약독화된 생균 균주
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7276353B2 (en) * 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
AU2003239805B2 (en) 2002-04-19 2009-09-10 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
EP1434858B2 (en) 2002-09-05 2018-12-19 Bavarian Nordic A/S Method for the amplification of a poxvirus under serum free conditions
DK1594970T3 (da) * 2003-02-18 2008-11-17 Helmholtz Zentrum Muenchen Fremgangsmåde til generering af rekombinant MVA
JP2005075752A (ja) * 2003-08-29 2005-03-24 Nippon Inst For Biological Science 豚繁殖・呼吸障害症候群用ワクチン製剤
US7788663B2 (en) * 2004-06-08 2010-08-31 Covia Labs, Inc. Method and system for device recruitment interoperability and assembling unified interoperating device constellation
EP1773387B1 (en) * 2004-06-25 2013-06-12 Merial Ltd. Avipox recombinants expressing foot and mouth disease virus genes
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
US8398994B2 (en) * 2005-07-15 2013-03-19 Boehringer Ingelheim Vetmedica, Inc. Lawsonia vaccine and methods of use thereof
EP1792996A1 (en) * 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
US8470336B2 (en) 2006-05-25 2013-06-25 Boehringer Ingelheim Vetmedica, Inc. Vaccination of young animals against Lawsonia intracellularis infections
WO2009029130A2 (en) * 2007-05-30 2009-03-05 Wyeth Raccoon poxvirus expressing genes of porcine virus
CL2008001806A1 (es) * 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
WO2009037262A2 (en) 2007-09-17 2009-03-26 Boehringer Ingelheim Vetmedica, Inc. Method of preventing early lawsonia intracellularis infections
KR101420850B1 (ko) * 2011-05-30 2014-08-13 건국대학교 산학협력단 돼지 생식기 호흡기 증후군 바이러스 유사입자 및 이를 이용한 백신
EP2714077B1 (en) * 2011-06-01 2018-02-28 Merial, Inc. Needle-free administration of prrsv vaccines
JPWO2016021276A1 (ja) * 2014-08-08 2017-05-25 出光興産株式会社 豚繁殖・呼吸障害症候群防除剤
DE102015111756A1 (de) 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
CN107236824A (zh) * 2017-06-29 2017-10-10 新希望六和股份有限公司 一种用于猪繁殖与呼吸综合征病毒特异性检测的荧光定量rt‑pcr试剂盒及应用
US20230241074A1 (en) * 2020-05-29 2023-08-03 University Of Connecticut Inhibitors of porcine reproductive and respiratory syndrome virus
CN116333060B (zh) * 2023-05-15 2023-07-21 广州悦洋生物技术有限公司 猪繁殖与呼吸综合征病毒gp5蛋白及其制备方法和用途、基因、试剂盒和检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
GB2289279B (en) * 1994-05-13 1998-09-16 Iberica Cyanamid Diagnostic kits and vaccines containing recombinant PRRSV proteins
AU729518B2 (en) * 1995-06-07 2001-02-01 Syntro Corporation Recombinant fowlpox viruses and uses thereof
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves

Also Published As

Publication number Publication date
WO2001089559A3 (en) 2002-04-11
CN1443076A (zh) 2003-09-17
PL360096A1 (en) 2004-09-06
ZA200210230B (en) 2003-10-27
BR0111366A (pt) 2003-05-20
KR20030036194A (ko) 2003-05-09
CA2409874A1 (en) 2001-11-29
JP2003533989A (ja) 2003-11-18
EP1283718A2 (en) 2003-02-19
AU2001256582A1 (en) 2001-12-03
WO2001089559A2 (en) 2001-11-29
US20030003112A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
PL352201A1 (en) Porcine circovirus vaccine in recombinant poxvirus
WO2001016330A3 (en) Prevention of affections associated with porcine circovirus-2
ATE430200T1 (de) Impstoff gegen den für atemwegs- und reproduktionserkrankungen beim schwein verantwortlichen virus
EE200300173A (et) Vaktsiiniaviirus, selle valmistamine ja kasutamine, seda sisaldav farmatseutiline kompositsioon ja vaktsiin ning meetod immuunreaktsiooni mõjutamiseks
MA27699A1 (fr) Vaccin contre vhc
GR3035458T3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
DE69936977D1 (de) Durch polynukleinsäuren vom reproduktiven und respiratorischen syndromvirus des schweines kodierte proteine
DK1090033T3 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
TW200740454A (en) Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus
ID24174A (id) Vector dari porcine adenovirus
BR0312474A (pt) Partìcula viral adjuvante
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
ECSP024257A (es) Proteinas antigenas del virus de la enfermedad de la mancha blanca en el camaron y usos de las mismas
BR112022004027A2 (pt) Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte
RU2015113826A (ru) Выделение вируса, родственного парвовирусу-2 собак, от енота
NO20060675L (no) Forbedrede, rekombinante, humane interferon-beta-lb-polypeptider
WO1999053950A3 (en) Live vaccines and methods of treatment therewith
EA200200743A1 (ru) Рекомбинантное ослабление вируса репродуктивного и респираторного синдрома свиней (prrsv)
NZ512341A (en) Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
MX2022015489A (es) Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
BR0112486A (pt) Poliproteìna, molécula de ácido nucleico, plasmìdeo, vacina recombinante ou vacina atenuada, composição farmacêutica, e, método para imunizar um indivìduo contra hiv
BR0108442A (pt) Mutantes-ehv gm-negativos
TR200202169T1 (tr) Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri.